Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon(®) Transdermal Patch (Daily)- A Randomized Clinical Trial

Background: Rivastigmine, a reversible AChEI for symptomatic treatment of mild to moderately severe Alzheimer’s dementia, is administered once daily transdermal patches, enabling an easier and continuous drug delivery. A novel multi-day (twice week) patch formulation was developed with greater conve...

Descripción completa

Detalles Bibliográficos
Autores principales: Schurad, Bjoern, Koch, Cornelius, Schug, Barbara, Morte, Adelaida, Vaqué, Anna, De la Torre, Rafael, Iniesta, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186381/
https://www.ncbi.nlm.nih.gov/pubmed/36017827
http://dx.doi.org/10.2174/1567205019666220823105059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186381/
https://www.ncbi.nlm.nih.gov/pubmed/36017827
http://dx.doi.org/10.2174/1567205019666220823105059

Ejemplares similares